Pictet Asset Management SA Increases Stake in Teva Pharmaceutical Industries,

In recent news, it has been revealed that Pictet Asset Management SA has increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.3% during the 1st quarter of this year. This information was disclosed in the company’s most recent filing with the Securities & Exchange Commission. It is now known that Pictet Asset Management SA owns a total of 363,785 shares in Teva Pharmaceutical Industries, after acquiring an additional 18,200 shares during this period. The value of these holdings at the end of the most recent quarter amounted to $3,219,000.

This development comes after Teva Pharmaceutical Industries recently announced its quarterly earnings results on August 2nd. The company reported an impressive $0.54 earnings per share for the quarter. This surpasses analysts’ consensus estimates by $0.02. Additionally, Teva Pharmaceutical Industries recorded revenue of $3.88 billion, exceeding analyst expectations of $3.69 billion.

The positive return on equity of 27.93% and negative net margin of 14.87% were also significant factors to consider in evaluating the performance of Teva Pharmaceutical Industries.

Looking ahead, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will continue to perform well for the remainder of the fiscal year, with an anticipated earnings per share of 2.16.

Investors and stakeholders in the pharmaceutical industry should keep a close eye on developments within Teva Pharmaceutical Industries as it continues to make waves in the market with its strong quarterly results and growing interest from influential asset management firms like Pictet Asset Management SA.

Overall, this latest update highlights Pictet Asset Management SA’s confidence in and support for Teva Pharmaceutical Industries Limited, further solidifying its position as a key player in the pharmaceutical sector.
References:
– Pictet Asset Management SA’s disclosure with the Securities & Exchange Commission
– Quarterly earnings results for Teva Pharmaceutical Industries on August 2nd.

Hedge Funds and Institutional Investors Make Moves on Teva Pharmaceutical Industries, Analysts Issue Ratings, and Insiders Sell Shares

Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company, has recently seen changes in ownership by several hedge funds and institutional investors. Money Concepts Capital Corp, International Assets Investment Management LLC, Toronto Dominion Bank, Spire Wealth Management, and U.S. Capital Wealth Advisors LLC have all either added to or reduced their stakes in Teva.

Money Concepts Capital Corp acquired a new position in Teva Pharmaceutical Industries during the fourth quarter of 2022. The purchase was valued at approximately $25,000. Similarly, International Assets Investment Management LLC also bought a new position in the company during the first quarter of 2023, estimated at around $26,000. In addition to this, Toronto Dominion Bank purchased shares worth $31,000 during the fourth quarter of last year.

Spire Wealth Management increased its holdings in Teva Pharmaceutical Industries by an impressive 49.8% during the first quarter of 2023. They now own 4,209 shares of the company’s stock valued at $37,000 after adding an additional 1,400 shares to their portfolio. Lastly, U.S. Capital Wealth Advisors LLC made a new investment in Teva Pharmaceutical Industries during the fourth quarter of 2022 with a value of about $54,000.

These recent moves indicate interest from various stakeholders in Teva’s potential for growth and future success. With institutional investors owning nearly half (49.69%) of the company’s stock, it is clear that there is significant confidence in Teva’s performance and prospects.

Equity analysts have also been closely following Teva Pharmaceutical Industries and providing recommendations on its stock. UBS Group raised their rating for the company from “sell” to “neutral” and increased their price target from $7.00 to $8.00 on July 6th this year. Evercore ISI also upgraded Teva from an “in-line” rating to an “outperform” rating on May 18th. StockNews.com initiated coverage on the company on August 17th with a “buy” rating, while Morgan Stanley gave it an “equal weight” rating and set a target price of $10.00 per share back in May. Overall, analysts have issued two sell…